From the beginning of the genetic revolution when the double helix DNA model was first described in the 1950s, to...
Read moreA single-dose gene therapy for neovascular age-related macular degeneration (nAMD) is now in Phase 3 clinical trials and, if approved,...
Read moreInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited